B-cell malignancies are a heterogeneous group of lymphoproliferative disorders with different molecular characteristics and clinical course. It is increasingly recognized that the group displays considerable heterogeneity also regarding aetiologic factors. Here, we summarize the latest developments in the aetiology of B-cell lymphoid malignancy subtypes focusing on immune perturbation. Severe immune suppression constitutes a strong and well-established risk factor for aggressive subtypes (e.g. diffuse large B-cell and Burkitt lymphoma), but appears unrelated to risk of common low-grade subtypes (e.g. follicular and mantle cell lymphoma). Inflammation and infections are known co-factors amongst the immunosuppressed; however, immune stimulation is now recognized as a crucial determinant of lymphomagenesis also amongst immunocompetent individuals. This is best exemplified in marginal zone lymphomas where local chronic inflammation and infection in the stomach, ocular adnexa and salivary glands have been directly linked with the development of oligoclonal and monoclonal malignant B-cell populations. Aggressive subtypes (e.g. diffuse large B-cell lymphoma) are increasingly linked with features of systemic immune stimulation including autoimmune/inflammatory disease and subclinical cytokine elevations. Lifestyle factors (e.g. high body mass index, cigarette smoking) are associated with risk of diffuse large B-cell and follicular lymphoma, respectively, possibly mediated through inflammation. Recent genome-wide association studies further underline the importance of immune function by linking several subtypes to variations in the human leucocyte antigen (HLA) class genes. In the future, improved knowledge of mechanistic pathways of inflammation/infections in lymphoma development may translate to active measures of prevention or treatment, as is already the case for some low-grade lymphoma subtypes.
Introduction B-cell lymphoid malignancies represent neoplastic transformation of B lymphocytes at their varying stages of differentiation and maturation. In studies of the epidemiology and aetiology of this group, the largely overlapping term non-Hodgkin lymphoma (NHL) is frequently used although this term is no longer applied in the current version of the international WHO classification [1] . About 90% of all NHLs arise from B cells, whereas the remaining 10% are lymphoid malignancies of T-or NK-cell origin. The rise in incidence of NHL in the latter half of the twentieth century sparked intense research efforts into the causes of this disease group, and important knowledge has been gained. During normal cell maturation, B lymphocytes are subject to a large number of potentially oncogenic events as part of the adaptive immune response [1] . However, epidemiological clues such as differences in incidence by sex, age and ethnicity as well as the previous rise in incidence imply that not only genetic events occurring by chance but also environmental and constitutional factors determine occurrence of these malignancies [2] . So far,
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factors that seem to potentiate adverse genetic events and contribute to malignant B-cell transformation can be classified in the three broad groups, i.e. heredity and germ line genetic susceptibility, immune suppression (including HIV/AIDS and organ transplantation) and immune stimulation (including chronic inflammation and infections). Furthermore, there is evidence to suggest that these factors also act in concert [3, 4] . Other external potentially carcinogenic exposures such as pesticides and solvents have been extensively studied in risk of NHL, but robust evidence of causal links have not yet been presented [5] . The recognition of aetiologic heterogeneity within the group of B-cell lymphoid malignancies has proved an important prerequisite to advance the understanding of underlying causes and mechanisms of lymphomagenesis, although commonalities also exist [6] . Here, we provide a broad overview of the epidemiology and aetiology of B-cell lymphoid malignancy subtypes with a focus on aetiologic determinants related to inflammation and infection (Table 1) .
Incidence trends
The incidence of lymphoid malignancies of NHL type is highest in the USA and Canada, with an incidence amongst whites of about 14 per 100 000 person-years, and lowest in Asian countries with an incidence of around 2 per 100 000 person-years [7] . In the USA, incidence is higher amongst white people than black people, although differences vary by B-cell malignancy subtype. Rates also differ by sex and are mostly higher amongst males, although the male predominance is not observed for a few subtypes, e.g. follicular lymphoma. The incidence increases steeply with age for almost all subtypes with some exceptions including Burkitt lymphoma and B-lymphoblastic leukaemia/lymphoma [8] .
In most Western countries, a pronounced increase in incidence of NHL was observed during the latter half of the twentieth century, with increases mounting to a few per cent annually [9, 10] . Increasing rates have notably also been observed in some Asian countries like India and Singapore. In many countries, including in Europe and the USA, the incidence levelled off in the mid-1990s. It has been concluded that the observed increase cannot be explained by changes in diagnostic and/or classification practices, nor by established risk factors [11] . Trends in incidence of B-cell lymphoid malignancy subtypes have been less studied and are complicated by changes in the subtype definitions and classifications. In particular, aggressive NHL subtypes were found to have increased in the late twentieth century in a US study, especially amongst males [12] , which could in part be explained by the HIV epidemic. Over the turn of the century, rates were instead found to have increased for marginal zone lymphoma and mantle cell lymphoma [8] , although this may in part have been explained by a decline in NHL/lymphoma not otherwise specified.
Risk factors for lymphoid malignancies

Family history and inherited susceptibility
Hematolymphoproliferative malignancies including NHL have been reported to be associated with modestly (two-to three-fold) increased familial risks in several studies [13] . Chronic lymphocytic leukaemia has been observed to have a more substantial familial component with up to seven-fold increased risks of the same malignancy amongst first-degree family members [14] . Based on these findings, large multicentre genome-wide association studies have been launched to uncover underlying genetic variants contributing to the heritability of the disease. For major NHL subtypes, as well as Hodgkin lymphoma and chronic lymphocytic leukaemia, a large number of low-penetrance germ line susceptibility variants have been successfully discovered through collaboration within the InterLymph consortium. The InterLymph consortium is an open scientific forum for epidemiologic lymphoma research that was initiated in the year 2001 (http://epi.grants.cancer.gov/Inte rLymph/). Member investigators at more than 25 international centres collaborate and perform research projects that pool data across studies.
Numerous recent studies have led to vastly improved understanding of genetic risk determinants that are both common to several B-cell malignancy subtypes and specific to one subtype in other instances. Variation in the 8q24 region implicated in MYC activation has proven to be associated with risk of both follicular and diffuse large B-cell lymphoma as well as chronic lymphocytic leukaemia [15] [16] [17] and are reported to have a role in the susceptibility of various other cancer forms. In chronic lymphocytic leukaemia, about 40 susceptibility loci have been detected in total so far, still however explaining only about 25% of the heritable risk [18] . Discovered loci annotate genes that are central to pathways of B-cell development, and in particular involve B-cell receptor mediated signalling with immune responses and apoptosis [18] .
Along the same lines, several other lymphoid malignancies are also associated with variation in genetic regions of importance for the function of the immune system, in particular the HLA region. Follicular lymphoma, but also marginal zone and diffuse large B-cell lymphoma have been associated with variation in the HLA class II region, regulating antigen presentation to T helper and T cytotoxic cells [15, 16, 19] . For diffuse large B-cell lymphoma, another strong susceptibility variant is located at 6p25, near the EXOC2 (exocyst complex component 2), of importance for host defence and cell death regulation [16] . From a clinical perspective, most identified genetic susceptibility loci are associated with modest risks (relative risk 0.5 to 2.0), and the underlying implications for lymphomagenesis have not yet been fully revealed. Therefore, screening amongst family members of sporadic B-cell malignancies cannot yet be recommended in the clinical routine [13] .
Additionally, lymphoid malignancies are known to occur at increased frequency amongst individuals with rare inherited defects of immune function, such as Wiskott-Aldrich syndrome and Nijmegen breakage syndrome, ataxia-telangiectasia, X-linked lymphoproliferative disorder, severe combined immunodeficiency and common variable immunodeficiency, hyper-IgM syndrome and autoimmune lymphoproliferative syndrome [7] . However, these genetic disorders explain few new cases in the general population. The mechanisms involve abnormal DNA repair function (ataxiatelangiectasia, Nijmegen breakage syndrome), loss of T-cell control (Wiskott-Aldrich syndrome), apoptosis defects (autoimmune lymphoproliferative syndrome), defective T-cell/B-cell interactions (hyper-IgM-syndrome) and chronic antigen stimulation (common variable immunodeficiency).
Immune suppression
It has been known for several decades that severe immune suppression is linked with an increased occurrence of lymphoid malignancies. Acquired states of severe immune suppression that are strongly and consistently linked include HIV/AIDS and organ transplantation [4] . The majority of immunodeficiency-related lymphoid malignancies feature similar clinical characteristics such as diffuse large B-cell histology and aggressive clinical course, extranodal location and an association with Epstein-Barr virus (EBV) [4] .
Before the introduction of antiretroviral therapy, the relative risk of NHL in HIV-infected individuals was on average 100-fold elevated [20] . Subsequent to increasing CD4 counts amongst treated individuals, NHL incidence has decreased dramatically in HIV-infected persons. However, an about 10-fold risk is still evident [20] . The remaining risk could have to do with direct viral effects and/or B-cell activation adding to the complexity of lymphomagenesis in this setting [4] . It is also worth noting that some lymphoma subtypes, primarily of low-grade histology such as follicular lymphoma and mantle cell lymphoma, do not occur more frequently amongst immunosuppressed compared to the general population [21] , implying a completely different aetiology of these subtypes.
Immunosuppressive therapy following solid organ or stem cell transplantation has also been observed to dramatically increase risks of NHL in numerous reports. The risk of NHL is about 20-fold increased in renal allograft recipients and up to about 200-fold in heart-transplant recipients, compared to the population [22] . Post-transplant lymphoproliferative disorders range from early EBV-driven polyclonal proliferations to EBV-positive (80-90%) or EBVnegative NHL, predominantly of B-cell origin [1] . Interestingly however, and in line with the setting of HIV/AIDS, some lymphoma subtypes such as follicular lymphoma and mantle cell lymphoma do not occur with increased frequency amongst organ transplant recipients [23] . EBV-positive lesions typically arise early following transplantation when immunosuppressive treatment doses are high, whereas EBV-negative post-transplant lymphomas may arise due to other mechanisms associated with sustained immunosuppression and aberrant lymphocyte proliferation [20] . Apart from the intensity and duration of the immunosuppressive treatment and EBV status of the donor and recipient, other factors of importance for determination of lymphoma risk post-transplantation are HLA type and mismatch likely implying an additional role for chronic immune stimulation [24] .
Infections
During the last decades, several studies have reported associations between infectious agents, including mostly bacteria and viruses, and lymphoproliferative disorders of various types, encompassing either indolent and aggressive clinicopathological entities ( In fact, this association relies on epidemiological [25] and histopathological [1] , as well as molecular data (reviewed in [26] , supported also by animal models [27] . Hp causes chronic active gastritis whose persistence in some instances is thought to lead to lymphoma development through a multistep process involving a Th1-type immune response, B-cell activation and proliferation [26] (Fig. 1) . Additional mechanisms include Hp-associated impairment of cytotoxic T-cell response and chromosomal translocations, perhaps potentiated through genetic susceptibility, exerting anti-apoptotic effects and activation of the NF-Kß pathway. Equally important, further evidence is derived from successful therapy in these lymphomas obtained with antibiotic therapy (see section on therapeutic implications below).
The link between Chlamydia psittaci infection and MALT-L of ocular adnexa accounts for the second most extensively evaluated association [28] . Evidence of an association relies on immunohistochemical, electron microscopic and laser capture-assisted molecular approaches [29] with further confirmation in ex-vivo cultures [30] , epidemiological studies [31] and through response to eradicating antibiotic therapy. This pathogenic link shows geographical variability, meaning that the highest prevalence of this bacterium has been reported in Italy and Korea, whilst the lowest figures have been reported from the US East Coast and Japan. Molecular analysis of immunoglobulins in ocular adnexal MALT-L indicates pathogenic mechanisms characterized by auto-reactivity [32] . These and other results suggest that ocular adnexal MALT-L originate from B cells binding auto-antigens in particular and that a pre-existing inflammatory background contribute to the pathogenesis (Fig. 1) . For other bacteria, the evidence of aetiologic associations is weaker. Borrelia burdgoferi (Bb) has been linked to cutaneous MALT-L by molecular methods in a limited patient series [33] . However, associations have primarily been reported from Europe and not the USA [34] . In a Scandinavian study, self-reported as well as serologic evidence of past Borrelia infection was linked with an increased risk of mantle cell lymphoma [35] . However, this finding has not yet been confirmed in other studies. A few reports also describe an association between Campylobacter jejuni and Immmunoproliferative Small Intestinal Disease [36] and Achromobacter Xylosoxidans and MALT-L of the lung [37] . Most recently, an increased risk of developing B-cell lymphomas has been described in patients with Q fever, which is caused by Coxiella burnetii infection [38] .
With regard to viruses, the association with some types of lymphomas is well established, although the pathogenetic mechanisms have not yet been fully elucidated. In particular, human herpesvirus 8 (HHV8) is detected in most if not all primary effusion lymphomas [39] , whereas EBV is present in nearly 100% of endemic Burkitt lymphoma (less frequently in its HIV-associated and sporadic forms), as well as in HIV-related Hodgkin lymphoma [40] . HCV infection has been associated with splenic marginal zone lymphoma and with to a lesser extent, some DLBCL [41] . Although hepatitis B has been reported to increase lymphoma risk [42] , pathogenetic data are much less clear, and an association has yet to be established. GB virus-C, formerly called Hepatitis G virus, has been associated with risk of NHL, and DLBCL in particular, but associations have so far only been noted with viraemia and not with antibody levels [43, 44] . As outlined above, HIV is believed to be associated with lymphomagenesis primarily through the ensuing immunosuppressive state rather than through mechanisms exerted by the virus per se.
Autoimmune and chronic inflammatory diseases
Autoimmune disorders constitute well-established risk factors for malignant lymphomas. Disorders most consistently associated with increased risks include Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis, coeliac disease and dermatitis herpetiformis [45, 46] . Also, chronic inflammatory conditions such as Crohn's disease [47, 48] and psoriasis [49] have often but not always been linked to increased lymphoma risks. An array of other immune-mediated disorders such as haemolytic anaemia, myositis and idiopathic trombocyopenic purpura have also been linked with lymphoma risk [45] , although risks have been observed to peak around the time of diagnosis of the lymphoma, implying that these disorders may primarily occur as paramalignant autoimmune phenomena. However, causal associations cannot be excluded.
The mechanisms of lymphomagenesis in autoimmune and inflammatory disorders, and the question whether immunosuppressive or biological therapy is safe to administer, have been a subject of intense research efforts in recent years. There is strong evidence to support a causal relationship with the underlying disease and its severity [46, 50] , making it even more difficult to disentagle drug-specific associations from those of treatment indications. Severe Sj€ ogren's syndrome, characterized by hypocomplementemia, palpable purpura, parotid enlargement and low T CD4+ cell counts have been linked with more pronounced risks of NHL [51] . Further, lymphomas have been reported to occur primarily amongst untreated Sjogren patients, thus underscoring the importance of inflammatory determinants and the lack of a role for immunosuppressive treatment in this setting [52] . The most commonly occurring lymphoma subtype amongst Sjogren patients is MALT lymphoma of the salivary glands; it is likely that the lymphomagenetic mechanism in these anatomical sites may be the result of a sustained inflammatory background where a prolonged polyclonal B-cell stimulation eventually evolves into a monoclonal, progressively independent expansion of B cells. Interestingly, some MALT-L developing within this background has been linked with HCV infection. It should be noted that Sjogren's syndrome has been associated also with extrasalivary glands lymphomas such as DLBCL [45] .
In rheumatoid arthritis, disease activity classified through medical records review was strongly associated with NHL risk in a large nested case-control study in Sweden [53] . Medium activity conferred an eight-fold increased risk, and high activity a 70-fold risk increase, compared to low disease activity when taking the confounding effect of treatment into account [53] . Logically, it was concluded that the lymphoma risk may be restricted to the patients with the most severe rheumatoid arthritis disease. The association with disease activity was further most evident for the DLBCL subtype, and within the DLBCL subset, for the activated B-cell type [54] . Interestingly, several other autoimmune and inflammatory conditions have been associated specifically with the DLBCL subtype, including coeliac disease and systemic lupus erythematosus [46] .
At present, there is no convincing evidence that immunosuppressive or biological therapy, e.g. with tumour necrosis factor antagonists, often given for autoimmune conditions, may cause an increase in lymphoma incidence [55] , although it cannot be entirely excluded either. In contrast, in Chron's disease, evidence is accumulating of a link between thiopurine medication and NHL risk [48] .
Other factors potentially related to immune activation and lymphoma risk
Certain environmental factors such as obesity and tobacco smoking have been suggested as risk factors for B-cell lymphoid malignancies through immune stimulation or other mechanisms, whereas other factors including ultraviolet radiation exposure has been suggested as protective factors [6, 56] . High body mass index (BMI) has consistently been associated with risk of lymphoma, DLBCL in particular, in several studies [57, 58] . In a recent meta-analysis of 16 studies, a 14% increase in incidence of diffuse large B-cell lymphoma was noted for each 10 kg m À2 increase in BMI. Because obesity can be characterized as a chronic inflammatory state, it is especially interesting to note the suggestive association with DLBCL, since this subtype has been specifically associated with diseases characterized by inflammation (see above). There is increasing evidence to suggest an association between cigarette smoking and risk of follicular lymphoma, particularly amongst women [59] , but not with lymphomas overall. Smoking may lead to chronic airway inflammation, but it may also induce the chromosomal translocation t(14;18) [60] , which is found in 70% to 95% of follicular lymphomas.
Regarding exposure to ultraviolet radiation through the sun, most observations to date support a possible protective effect of ultraviolet radiation on lymphomagenesis [61, 62] . Inverse associations have been described for several NHL subtypes, but most consistently for DLBCL [62, 63] . Ultraviolet radiation-induced effects on the immune system are incompletely understood, but may include increased levels of suppressor T-cells, a shift towards a Th2-type response, and a general downregulation of antigen-presenting activity [64] .
Additional support for a role of immune activation and inflammation in lymphoma aetiology also amongst individuals without a diagnosis of an inflammatory disease has been provided from recent biomarker studies based on large prospective cohorts. Levels in serum of soluble B-lymphocyte surface receptors and different cytokines have been associated with risk of several subtypes of NHL of both aggressive and indolent nature [65] .
Associations have been observed amongst lymphoma cases diagnosed up to 20 years after the prospective blood sampling, suggesting that increased serum levels of these factors precede lymphoma development rather than providing a reflection of disease activity. More research is, however, needed to understand the nature and timing of these observations and to what extent they may be able to explain mechanisms of lymphomagenesis.
Therapeutic implications
Established links between bacteria and lymphomas have consequences at the therapeutic level (Table 1) , and response to antibiotics per se imply their active role in lymphomagenesis. Hp infection is paradigmatic, and the current standard treatment of Hp-associated gastric MALT-L is represented by the eradication of this bacterium with combined proton-pump inhibitor plus clarithromycin-based triple therapy with either amoxicillin or metronidazole [66] . This approach is estimated to enable a 75% remission rate. In the case of Chlamydia psittaci-associated MALT-L of ocular adnexa, three independent prospective trials, using 3-week course of doxycycline 100 mg bid, have demonstrated an overall response rate of 48% and 65% of patients, respectively. Chlamydia psittaci eradication was further associated with longer progression-free survival compared with noneradicated cases in a phase-II trial (Fig. 2 ) [67, 68] . In cutaneous MALT-L, first-line antibiotic therapy is considered potentially effective, although frequent unsuccessful results may occur [69] . In the setting of viral infection and lymphomas, interferon-based as well as direct-acting antiviral treatment regimens have induced tumour regression in patients with HCV-related indolent lymphomas, in particular splenic marginal zone lymphoma and MALT [70, 71] . Therefore, antiviral treatment only could be considered as first-line treatment in HCV-associated low-grade lymphomas according to recent guidelines [72] . Although HIV does not seem play a direct role in lymphomagenesis, sporadic data in the literature report the complete remission of HIV-associated primary central nervous system lymphoma obtained by the introduction of antiretroviral therapy as unique therapy [73] .
Given the established link between autoimmunity and inflammation, at least amongst patients diagnosed with such conditions, and lymphoma risk, it
The aetiology of B-cell malignancies / K. E. Smedby & M. Ponzoni is tempting to speculate that agents aiming to reduce the inflammatory activity could in fact have a preventive role. However, increased risks of lymphoma in, e.g. rheumatoid arthritis, that remain on average about two-fold increased in spite of more intense treatment schemes in recent years, argue against such a lymphoma-reducing benefit [74] . On another note, drugs used to treat both inflammatory diseases and lymphoma, e.g. corticosteroids and the anti-CD20 antibody, rituximab, could theoretically have preventive effects when used in the autoimmune/inflammatory setting. Lymphoma risk following steroid treatment has been evaluated on several occasions amongst patients with different inflammatory conditions but results have been mixed. In a retrospective observational study of lymphoma risk in patients with rheumatoid arthritis, steroids, both orally administered and intra-articular injections, were associated with a risk reduction [75] . Notably, in this study, the risk reduction associated with steroids was particularly pronounced for DLBCL. Rituximab is licensed for the use in RA, but may also be used off-label in diseases such as Sjogren's syndrome and systemic lupus erythematosus [76] , but if lymphoma risks have been modified following this treatment has not yet been evaluated. New drugs targeting B-cell receptor pathways, e.g. tyrosine kinase inhibitors may indeed be efficient for both autoimmune conditions and lymphoma and could offer potential for lymphoma prevention in the future.
Conclusions and future directions
For several decades, the incidence of NHL increased more rapidly than that of almost any other cancer. Well-established risk factors such as immunosuppression, autoimmunity/inflammation, and certain infectious agents explain at most only a small fraction of the cases, and thus cannot explain the past increase. However, more recent observations indicate that high body mass index and smoking may have contributed to some extent. Although the strong connection between immune modulation (deficiency as well as activation) and NHL risk suggests that we should keep searching for factors that influence immune modulation, new hypotheses are needed to further unravel the aetiology of NHL subtypes. Increasing knowledge of somatic mutations revealed through, e.g. next-generation sequencing, may aid in the identification of relevant risk factor areas. Additional infectious agents with lymphomagenetic potential are also likely to exist. Meanwhile, existing knowledge should be used to develop preventive and therapeutic strategies as relevant. [67] .
